Exicure Announces Presentation at 2021 H.C. Wainwright Global Life Sciences Conference
February 23 2021 - 7:00AM
Business Wire
Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and
immunotherapeutic drugs utilizing spherical nucleic acid (SNA™)
constructs, today announced that CEO David Giljohann will present
at the 2021 H.C. Wainwright Global Life Sciences Conference, March
9-10, 2021.
The presentation will be available to registered conference
attendees for on-demand viewing beginning March 9, 2021 at 7:00AM
EST via the virtual conference link, and will be archived for 90
days.
Exicure will be taking 1x1 investor meetings with registered
conference attendees.
Replays of the presentation will be available on Exicure’s
website for 30 days following the presentation.
About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company
developing therapeutics for neurology, immuno-oncology,
inflammatory diseases and other genetic disorders based on our
proprietary Spherical Nucleic Acid, or SNA technology. Exicure
believes that its proprietary SNA architecture has distinct
chemical and biological properties that may provide advantages over
other nucleic acid therapeutics and may have therapeutic potential
to target diseases not typically addressed with other nucleic acid
therapeutics. Exicure is in preclinical development of XCUR-FXN an
SNA–based therapeutic candidate, for the treatment of Friedreich’s
ataxia (FA). Exicure's drug candidate AST-008 is currently in a
Phase 1b/2 clinical trial in patients with advanced solid tumors.
Exicure is in Chicago, IL and has an office in Cambridge, MA.
For more information, visit Exicure’s website at
www.exicuretx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210223005074/en/
Karen Sharma MacDougall 781-235-3060 ksharma@macbiocom.com
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jul 2023 to Jul 2024